An FDA committee of experts this summer voted overwhelmingly against approval of AstraZeneca's new ovarian cancer treatment. But reviewers for the EMA gave it a nod for use on patients with platinum-sensitive ovarian cancer and BRCA mutations, FierceBiotech reports.
European regulators have recommended an early approval for AstraZeneca's new ovarian cancer treatment, welcome news for the company as it defends rosy sales estimates for its oncology pipeline.
Pfizer's $11 billion share buyback, announced late Thursday, gave investors something to focus on, rather than fretting about whether the company would renew its pursuit of AstraZeneca once the required cooling off period lapses in November. But some of them immediately started worrying about whether the buyback meant it was less likely Pfizer would do a big deal.
Will Pfizer come back at AstraZeneca? That's been the question of the summer, especially since the U.S. Treasury Department rolled out new rules for tax-inversion deals.
AstraZeneca, two years away from a big relocation to Cambridge, U.K., is broadening its relationship with the local university, signing a slew of new agreements that will bolster its R&D efforts in neuroscience and oncology.
AstraZeneca is expecting word from European regulators next week on whether they'll recommend approval for its new ovarian cancer treatment, a drug the company hopes can bring in $2 billion a year at its peak.
AstraZeneca has launched a photo-sharing campaign on Twitter, Instagram and other social media sites to get women talking about their metastatic breast cancer (MBC).
Pharma companies are no stranger to photography-based disease awareness campaigns. But there's something different about AstraZeneca's latest breast cancer photo campaign: The photographers are the patients themselves.
Texas Attorney General Greg Abbott has sued AstraZeneca for fraud, saying that AstraZeneca sales reps misled doctors and state Medicaid officials about Seroquel's side effects, paid kickbacks to two influential state decision-makers, and promoted the powerful antipsychotic for off-label uses.
AstraZeneca is moving forward with a respiratory candidate developed alongside Charles River Laboratories' discovery business, a milestone the CRO says affirms its investments in the space.